| Literature DB >> 28090760 |
Leah Cannon1, Alexander C Zambon1,2, Anthony Cammarato3, Zhi Zhang1, Georg Vogler1, Matthew Munoz2, Erika Taylor1, Jérôme Cartry1, Sanford I Bernstein4, Simon Melov5, Rolf Bodmer1.
Abstract
Aging causes cardiac dysfunction, often leading to heart failure and death. The molecular basis of age-associated changes in cardiac structure and function is largely unknown. The fruit fly, Drosophila melanogaster, is well-suited to investigate the genetics of cardiac aging. Flies age rapidly over the course of weeks, benefit from many tools to easily manipulate their genome, and their heart has significant genetic and phenotypic similarities to the human heart. Here, we performed a cardiac-specific gene expression study on aging Drosophila and carried out a comparative meta-analysis with published rodent data. Pathway level transcriptome comparisons suggest that age-related, extra-cellular matrix remodeling and alterations in mitochondrial metabolism, protein handling, and contractile functions are conserved between Drosophila and rodent hearts. However, expression of only a few individual genes similarly changed over time between and even within species. We also examined gene expression in single fly hearts and found significant variability as has been reported in rodents. We propose that individuals may arrive at similar cardiac aging phenotypes via dissimilar transcriptional changes, including those in transcription factors and micro-RNAs. Finally, our data suggest the transcription factor Odd-skipped, which is essential for normal heart development, is also a crucial regulator of cardiac aging.Entities:
Keywords: LysX; MMP1; Odd-skipped; arrhythmia; cardiomyopathy; heart; nanofluidics; senescence
Mesh:
Substances:
Year: 2017 PMID: 28090760 PMCID: PMC5242310 DOI: 10.1111/acel.12559
Source DB: PubMed Journal: Aging Cell ISSN: 1474-9718 Impact factor: 9.304
Figure 1Heatmap of age‐related gene changes in the Drosophila heart with associated Gene Ontology terms and miR binding site enrichment. 5‐week‐old yw and yw x GMH5 fly hearts show significant up‐ and down‐regulation of 260 and 202 transcripts (corresponding with 239 and 193 unique genes) respectively compared with 1‐week‐old genotype matched controls (aging P‐value < 0.005, interaction P‐value > 0.05).
Figure 2GO terms enriched in up‐ and down‐regulated fly and rodent aging heart gene sets. Red indicates a significantly enriched process (Z>2); brighter color represents a higher Z score. Black indicates no significant enrichment (Z<2).
Figure 3Effect of modulating Odd‐skipped on heart function. (A) Hand4.2>Odd TRiP RNAi (grey) compared with control (black) at 1 and 7 weeks by two‐way ANOVA and Tukey's multiple comparison (**P = 0.01, *P < 0.05, n = 15–26). Heart Period and Arrhythmia Index exhibit a significant increase with age upon cardiac Odd RNAi knockdown. (B) Conditional cardiac overexpression (OE) with HandGS>Odd‐OE RU (grey) compared with control (black) at 1 and 6 weeks by two‐way ANOVA and Tukey's multiple comparison (n = 15–20, *P < 0.05, ****P < 0.0001). Cardiac Odd OE at young but not old age causes increased Heart Period, dilation and reduced contractility (decreased Fractional Shortening). (C) Representative M modes of control and Hand4.2>Odd RNAi hearts at 7 weeks and control and HandGS>Odd‐OE RU hearts at 1 week.
Figure 4Nanofluidic qPCR results of bioinformatically predicted Odd target genes. mRNA of Odd target genes Odd, LysX, Nep2 and TwdlF are significantly up‐regulated in 5 week hearts compared with 1 week controls (n = 15–16, permutation test < 0.05).
Figure 5Effect of modulating LysX or Mmp1 on heart function. (A) Hand4.2>LysX (grey bars) compared with control (black bars). Comparisons analyzed by two‐way ANOVA and Tukey multiple comparisons (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n = 8–20). (B) Hand4.2>Mmp1‐ (grey) compared with control (black) at 1 and 5 weeks. Comparisons analyzed by two‐way ANOVA and Tukey multiple comparisons (n = 15–30, *P < 0.05). (C) Representative M modes of control vs. Hand4.2>LysX at 7 weeks and control vs. Hand4.2>Mmp1‐ at 5 weeks.